An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Trial Status: active
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib
administered in combination with endocrine therapy in participants with
pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following
progression on or after at least two prior lines of endocrine therapy in the recurrent or
metastatic setting. This study is intended to evaluate the optimal alisertib dose
administered in combination with the selected endocrine therapy. The study is also
planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in
combination with endocrine and to identify the biomarker-defined subgroup(s) that may
benefit most from combined alisertib and endocrine therapy.
Inclusion Criteria
Aged ≥18 years at signing of informed consent.
Pathology-confirmed diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to curative therapy.
Progression on or after treatment with at least two prior lines of endocrine therapy in the recurrent or metastatic setting. a. If metastatic disease recurrence occurs during or within six months of discontinuing adjuvant endocrine therapy, then that endocrine therapy will count as one line of prior therapy.
Participants must have received a CDK4/6i in combination with endocrine therapy in the recurrent or metastatic setting.
HR-positive and HER2-negative tumor status reported per local laboratory testing. HR and HER2 testing must be performed consistent with current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) or European Society of Medical Oncology (ESMO) guidelines:
Exclusion Criteria
Treatment with chemotherapy in the recurrent or metastatic setting.
Prior treatment with an Aurora Kinase A (AURKA) specific-targeted or pan-Aurora-targeted agent, including alisertib, in any setting. Note: There are additional inclusion and exclusion criteria. The study center will
determine if you meet all of the criteria.
Additional locations may be listed on ClinicalTrials.gov for NCT06369285.
